EMEA-000060-PIP05-14-M01
Key facts
| Invented name |
Ilaris
|
| Active substance |
Canakinumab
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0239/2015
|
| PIP number |
EMEA-000060-PIP05-14-M01
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of tumour necrosis factor receptor associated periodic syndrome
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Novartis Europharm Ltd
|
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-000060-PIP05-14-M01
|
| Compliance opinion date |
26/02/2016
|
| Compliance outcome |
positive
|